{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-096478","form_type":"8-K","ticker":"OTLK","cik":"0001649989","company_name":"Outlook Therapeutics, Inc.","filed_at":"2026-08-14T12:00:49+00:00","discovered_at":"2026-08-14T12:05:01.402530+00:00","generated_at":"2026-08-14T12:05:39.870583+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Outlook Therapeutics reports Q3 FY2026 results; FDA-approved LYTENAVA launch planned by end of 2026","bullets":["Net loss $20.3M ($0.15/share) vs $20.2M ($0.55/share) YoY; adjusted net loss $10.9M ($0.09/share) vs $15.8M ($0.44/share).","Cash $11.2M at June 30, 2026; subsequent public offering raised ~$51.1M net from 55.6M shares at $0.99.","FDA approved LYTENAVA (bevacizumab-vikg) for wet AMD; U.S. launch planned before end of calendar 2026.","Management sees potential to exceed $500M annual U.S. sales by 2030; HCPCS code application by Oct 1, 2026.","European expansion: Germany, Austria, UK; Netherlands launch later 2026; Switzerland partner Mediconsult launch 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-096478","json":"https://secwatch.observer/filing/0001104659-26-096478.json","markdown":"https://secwatch.observer/filing/0001104659-26-096478.md","text":"https://secwatch.observer/filing/0001104659-26-096478.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649989/000110465926096478/0001104659-26-096478-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649989/000110465926096478/tm2622399d3_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-14T12:05:39.870583+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}